Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
Venkataramanan R et al. | Pharmacokinetics of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721261 |
Christians U et al. | High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. | 1991 | Transplant. Proc. | pmid:1721262 |
Beysens AJ et al. | FK 506: monitoring in plasma or in whole blood? | 1991 | Transplant. Proc. | pmid:1721263 |
Grenier FC et al. | A whole blood FK 506 assay for the IMx analyzer. | 1991 | Transplant. Proc. | pmid:1721264 |
Friob MC et al. | A combined HPLC-ELISA evaluation of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721265 |
McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
Akselband Y et al. | Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. | 1991 | Transplant. Proc. | pmid:1721292 |
Schreiber SL et al. | Immunophilin-ligand complexes as probes of intracellular signaling pathways. | 1991 | Transplant. Proc. | pmid:1721293 |
Ullman KS et al. | Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. | 1991 | Transplant. Proc. | pmid:1721294 |
Sigal NH et al. | Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? | 1991 | Transplant. Proc. | pmid:1721295 |
Bierer BE et al. | FK 506 and rapamycin: molecular probes of T-lymphocyte activation. | 1991 | Transplant. Proc. | pmid:1721296 |
Tanida I et al. | Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. | 1991 | Transplant. Proc. | pmid:1721297 |
Fukuzawa M et al. | Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. | 1991 | Transplant. Proc. | pmid:1721321 |
Takaori K et al. | Effects of FK 506 on in vivo immunity in comparison to cyclosporine. | 1991 | Transplant. Proc. | pmid:1721322 |
Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
Motta I et al. | FK 506 favors the generation of memory T cells in vitro. | 1991 | Transplant. Proc. | pmid:1721324 |
Nakata S et al. | Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. | 1991 | Transplant. Proc. | pmid:1721325 |
Cooper MH et al. | Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. | 1991 | Transplant. Proc. | pmid:1721326 |
Didlake R and Grogan J | Effect of FK 506 on rat leukocyte chemotaxis. | 1991 | Transplant. Proc. | pmid:1721327 |
Hultsch T and Hohman RJ | Categorizing receptor-signaling pathways with FK 506 and rapamycin. | 1991 | Transplant. Proc. | pmid:1721328 |
Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
Keicho N et al. | Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. | 1991 | Cell. Immunol. | pmid:1703047 |
Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
White DJ | FK506: the promise and the paradox. | 1991 | Clin. Exp. Immunol. | pmid:1703053 |
Whiteside TL et al. | Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721356 |
Frayha HH et al. | Lymphoproliferative disorder in a liver transplant patient on FK 506. | 1991 | Lancet | pmid:1703258 |
Van Thiel DH et al. | Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1721357 |
Burman K and Crawford DH | Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. | 1991 | Lancet | pmid:1703259 |
Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721358 |
Nalesnik MA et al. | Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. | 1991 | Transplant. Proc. | pmid:1703335 |
Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721359 |
Armitage JM et al. | A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1703336 |
Dew MA et al. | Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721360 |
Gordon RD et al. | Liver transplantation under cyclosporine: a decade of experience. | 1991 | Transplant. Proc. | pmid:1703339 |
Shapiro R et al. | FK 506 in clinical kidney transplantation. | 1991 | Transplant. Proc. | pmid:1721361 |
Todo S et al. | One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. | 1991 | Transplant. Proc. | pmid:1703340 |
Tauxe WN et al. | A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. | 1991 | Transplant. Proc. | pmid:1721386 |
McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
Hossein-Nia M et al. | Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721388 |
Winkler M et al. | Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. | 1991 | Transplant. Proc. | pmid:1721389 |
Schmidt RJ et al. | Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721390 |
Tze WJ et al. | Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. | 1991 | Transplant. Proc. | pmid:1721391 |
Doi R et al. | Mechanisms by which FK 506 affects exocrine pancreas in rats. | 1991 | Transplant. Proc. | pmid:1721392 |
Rilo HL et al. | Effect of FK 506 on function of human islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1721393 |
Tzakis AG et al. | FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721416 |
Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
Wiederrecht G et al. | FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1704127 |
Boggs S et al. | FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. | 1991 | Transplant. Proc. | pmid:1721420 |
Ziccardi VB et al. | Maxillofacial considerations in orthotopic liver transplantation. | 1991 | Oral Surg. Oral Med. Oral Pathol. | pmid:1704494 |
Cooper MH et al. | Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. | 1991 | Transplant. Proc. | pmid:1721421 |
Bierer BE et al. | The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. | 1991 | Eur. J. Immunol. | pmid:1705513 |
Yoshimi F et al. | Canine total orthotopic small bowel transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721422 |
Heitman J et al. | FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1705713 |
Santiago SF et al. | Effect of donor pretreatment with FK 506 upon small intestine allotransplantation in rats. | 1991 | Transplant. Proc. | pmid:1721423 |
Murase N et al. | Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721424 |
Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
Abu-Elmagd K et al. | Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. | 1991 | Transplant. Proc. | pmid:1721451 |
Thomson AW et al. | Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. | 1991 | Transplant. Proc. | pmid:1721452 |
Sigal NH et al. | Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. | 1991 | Transplant. Proc. | pmid:1712132 |
Sainsbury TS et al. | Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. | 1991 | Transplant. Proc. | pmid:1721453 |
Fung JJ et al. | Current status of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1712133 |
Fujino Y et al. | FK 506 treatment of experimental autoimmune uveoretinitis in primates. | 1991 | Transplant. Proc. | pmid:1721454 |
Francavilla A et al. | Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. | 1991 | Hepatology | pmid:1712337 |
Liversidge J et al. | FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. | 1991 | Transplant. Proc. | pmid:1721455 |
Aoki H | [FK 506, a new immunosuppressant produced by a Streptomyces]. | 1991 | Nippon Rinsho | pmid:1712403 |
Mochizuki M et al. | A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. | 1991 | Transplant. Proc. | pmid:1721456 |
Hultsch T et al. | Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1712484 |
Miyahara H et al. | Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. | 1991 | Clin. Immunol. Immunopathol. | pmid:1712688 |
McAlpine JB et al. | Revised NMR assignments for rapamycin. | 1991 | J. Antibiot. | pmid:1712766 |
Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
Katz IA et al. | Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. | 1991 | Transplantation | pmid:1716801 |
Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
Pezze JL and Whiteman K | Transplantation's newest weapon FK 506. | 1991 | Am J Nurs | pmid:1716857 |
Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
Baumann G et al. | Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. | 1991 | New Biol. | pmid:1715185 |
Marquis-Omer D et al. | Stabilization of the FK506 binding protein by ligand binding. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1716886 |
Wu J et al. | Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. | 1991 | Transplant. Proc. | pmid:1703683 |
Liu J et al. | Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. | 1991 | Cell | pmid:1715244 |
Sakai K et al. | [The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. | 1991 | No To Shinkei | pmid:1716937 |
Yoshimura R et al. | A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. | 1991 | Transplant. Proc. | pmid:1703686 |
Henderson DJ et al. | Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. | 1991 | Immunology | pmid:1715317 |
Miyagawa S et al. | Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. | 1991 | Transplant. Proc. | pmid:1703687 |
DeFranco AL | Signal transduction. Immunosuppressants at work. | 1991 | Nature | pmid:1715515 |
Carroll PB et al. | Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1703688 |
Flanagan WM et al. | Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. | 1991 | Nature | pmid:1715516 |
Fujino Y et al. | FK506 treatment of S-antigen induced uveitis in primates. | 1991 | Curr. Eye Res. | pmid:1717199 |
Sakr MF et al. | Protective effect of FK 506 against hepatic ischemia in rats. | 1991 | Transplant. Proc. | pmid:1703689 |
McWhinnie DL and Morris PJ | Combination drug therapies for immunosuppression in transplantation. | 1991 | Ann. Acad. Med. Singap. | pmid:1724724 |
Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |